To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question

被引：0
|
作者：
Lukasik, Zuzanna [1 ,2 ]
Carron, Philippe [1 ,2 ]
Webers, Casper [3 ,4 ]
机构：
[1] Univ Ghent, Ghent Univ Hosp, Dept Internal Med & Pediat, Ghent, Belgium
[2] VIB Ctr Inflammat Res, Ghent, Belgium
[3] Maastricht Univ, Med Ctr, Dept Internal Med, Div Rheumatol, Maastricht, Netherlands
[4] Maastricht Univ, Care & Publ Hlth Res Inst CAPHRI, Maastricht, Netherlands
来源：
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2023年 / 37卷 / 03期
关键词：
Axial spondyloarthritis; Tapering; Discontinuation; Remission; Therapy; Biological DMARD; SOCIETY CLASSIFICATION CRITERIA; ASAS-EULAR RECOMMENDATIONS; ANKYLOSING-SPONDYLITIS; PSORIATIC-ARTHRITIS; DOSE REDUCTION; PERIPHERAL SPONDYLOARTHRITIS; RHEUMATOID-ARTHRITIS; NON-INFERIORITY; TNF-INHIBITORS; DOUBLE-BLIND;
D O I：
10.1016/j.berh.2023.101869
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The 2022 ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) propose to consider dose reduction of biological disease-modifying antirheumatic drugs (bDMARDs) for patients in sustained remission. However, this recommendation does not offer clear guidance for daily clinical practice. In this review, we analyze randomized clinical trials and real-world data on tapering and discontinuation of bDMARDs in patients with axSpA. We discuss the scientific rationale and benefits of tapering, identify advice to apply tapering in current practice, and delineate aspects to be investigated in future research. (c) 2023 Elsevier Ltd. All rights reserved.
引用
收藏
页数：17
相关论文
共 50 条
  • [11] DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    SMITH, MD
    AHERN, MJ
    MEDICAL JOURNAL OF AUSTRALIA, 1992, 157 (11-12) : 797 - 801
  • [12] The Effect of Biologic Disease-Modifying Antirheumatic Drugs in Targeting Disease Remission in Axial Spondyloarthritis: A Systematic Literature Review
    Machado, Ana Rita
    Manica, Santiago Rodrigues
    Silva, Joana Leite
    Pimentel-Santos, Fernando
    Costa, Jose Tavares
    Vieira-Sousa, Elsa
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [13] Association of nociplastic and neuropathic pain components with the presence of residual symptoms in patients with axial spondyloarthritis receiving biological disease-modifying antirheumatic drugs
    Al Mohamad, Fares
    Rodriguez, Valeria Rios
    Haibel, Hildrun
    Protopopov, Mikhail
    Rademacher, Judith
    Sieper, Joachim
    Torgutalp, Murat
    Kaeding, Henriette
    Proft, Fabian
    Poddubnyy, Denis
    RMD OPEN, 2024, 10 (01):
  • [14] Safety of biological disease-modifying antirheumatic drugs in rheumatoid arthritis
    Martinez-Mugica, Cristina
    Salgueiro, Esther
    FARMACIA HOSPITALARIA, 2022, 46 (01) : 15 - 20
  • [15] THE EFFECT OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN TARGETING DISEASE REMISSION IN AXIAL SPONDYLOARTHRITIS (AXSPA): A SYSTEMATIC LITERATURE REVIEW
    Cruz-Machado, A. R.
    Manica, S. R.
    Silva, J. L.
    Pimentel-Santos, F. M.
    Tavares-Costas, J.
    Vieira-Sousa, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 998 - 999
  • [16] Update on recommendations for eligibility of government subsidization of biologic disease-modifying antirheumatic drugs for the treatment of axial spondyloarthritis in Singapore
    Phang, Kee Fong
    Lahiri, Manjari
    Fong, Warren Weng Seng
    Leong, Keng Hong
    Leung, Ying Ying
    Lim, Anita Yee Nah
    Lui, Nai Lee
    Manghani, Mona
    Tan, Teck Choon
    Santosa, Amelia
    Sriranganathan, Melonie Kannamma
    Suresh, Ernest
    Teng, Gim Gee
    Cheung, Peter P.
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2020, 23 (02) : 165 - 173
  • [17] Modern disease-modifying antirheumatic drugs
    Mueller-Ladner, U.
    Richter, K.
    Tarner, I. H.
    INTERNIST, 2015, 56 (03): : 307 - 314
  • [18] Development of a web-based decision aid for initiating biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in axial spondyloarthritis
    Beckers, Esther
    Boonen, Annelies
    van Tubergen, Astrid
    RMD OPEN, 2023, 9 (02):
  • [19] The Association between the Biological Disease-Modifying Antirheumatic Drugs and Incidence of Diabetes
    Lin, Chu
    Ji, Hongyu
    Cai, Xiaoling
    Yang, Wenjia
    Ji, Linong
    DIABETES, 2020, 69
  • [20] Nonsteroidal Antiinflammatory Drugs as Potential Disease-Modifying Medications in Axial Spondyloarthritis
    Wang, Runsheng
    Bathon, Joan M.
    Ward, Michael M.
    ARTHRITIS & RHEUMATOLOGY, 2020, 72 (04) : 518 - 528
12345